Mark Engel

Mark Engel is an experienced entrepreneur and executive in the life sciences industry, with a focus on biotechnology and pharmaceuticals. He is currently the Chairman and CEO of Precisio Biotix Therapeutics, a company developing biological antibacterials.12

Career Highlights

Precisio Biotix and Subsidiaries::

• Founder of Phagelux, a subsidiary of Precisio Biotix, which creates phage-based topical solutions for antimicrobial-resistant skin conditions.1
• CEO of Phagelux, Inc., which recently changed the name of its Wuhan-based subsidiary to Lysigen.3

Other Current Roles::

• Chairman of Phagelux AgriHealth, developing phage-based solutions for crop sciences, food safety, and animal health.1
• Managing Director of Tianshi Capital, an early-stage investor in life sciences.12
• Director at Haoyisheng.com, a leading healthcare technology company in China.1

Entrepreneurial Background

Mark Engel has a track record of founding and building successful life sciences companies since 1990, particularly in China. Some of his previous ventures include:

• NPO Pharmaceutical (sold)
• Excel PharmaStudies (sold to PPD in 2009)
• Tiger Medical Group (sold)
• Haoyisheng ("Good Doctor")2

Expertise

Engel has rich experience in new drug registrations and product commercialization. His focus at Precisio Biotix and its subsidiaries is on developing biological antibacterials, with an emphasis on topical treatments for difficult-to-treat diseases.12

Education

While not explicitly stated in the provided search results, Engel's LinkedIn profile indicates he has a background in business and marketing, with experience at companies like General Mills and SC Johnson earlier in his career.4